1. Albers, G. W., Atkinson, R. P., Kelley, R. E., and Rosenbaum, D. (on behalf of the Dextrorphan Study Group), Safety, tolerability, and pharmakokinetics of the N-methylD-aspartate antagonist dextrorphan in patients with acute stroke, Stroke, 26 (1995) 254–258.
2. Grotta, J., Clark, W., Coull, B., Pettigrew, L. C., Mackay, B., Goldstein, L. B., Meissner, I., Murphy, D., and LaRue, L., Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial, Stroke, 26 (1995) 602–605.
3. Steinberg, G. K., Bell, T. E., and Yenari, M. A., Dose escalation safety and tolerance study of the NMDA antagonist, dextromethorphanin neurosurgical patients, J. Neurosurg., 84 (1996) 860–866.
4. Steinberg, G. K., Perez-Pinzon, M. A., Maier, C. M., Sun, G. H., Yoon, E., Kunis, D. M., Bell, T. E., Powell, M., Kotake, A., and Giffard, R. G., CGS 19755 (selfotel): Correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients, in J. Krieglstein and H. Oberpichler-Schwenk (eds.), Pharmacology of Cerebral Ischemia, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1994, pp. 225–232.
5. Albers, G. W., Potential therapeutic uses of N-methyl-D-aspartate antagonists in cerebral ischemia, Clin. Neuropharmacol., 13 (1990) 177–197.